高血压病的治疗-培训课件.pptVIP

3天后冠状动脉造影显示血管内无血栓，但远断分叉处90%狭窄 其它治疗 心力衰竭的外科治疗： ——心室减容手术 ——左心辅助装置 ——心脏移植 埋藏式左心辅助泵 全面控制心脑血管病危险因素减少心脑血管病并发症的发生 提高国民健康水平 * * * * 在生活压力和工作压力之下，身心疲惫的中年人往往采取不健康的生活方式减压。市场竞争的残酷压力使一些中年人患有代谢紊乱综合症，甚至导致中风、冠心病的提早发生。心脑血管病专家认为，造成中年人猝死的原因多是心脏问题，且心脑血管疾病患者正趋于年轻化。 医学专家提醒，预防心脑血管疾病猝死应该从青年开始，30-40岁的人更应该有自我保健意识，定期到医院进行身体检查，戒烟限酒，当你感到疲劳是最好卧床休息。 * * * Slide 19: LIIFE: Comparable Blood Pressure Reductions Both losartan and atenolol substantially reduced systolic and diastolic blood pressures (-30.2/16.6 mmHg with losartan; -29.1/16.8 with atenolol).1 The target blood pressure of 140/90 mmHg was achieved by 49 % of patients treated with losartan and 46% of patients treated with atenolol.1 When adjusting for these minor differences in BP lowering, the significant reduction in risk of the combined primary endpoint of cardiovascular morbidity and mortality was not affected in any appreciable manner.1 * Slide 21: LIIFE: Change from Baseline in LVH Regression Compared to the atenolol treatment group, treatment with losartan resulted in a significantly greater regression of LVH from baseline (10.2% with losartan vs. 4.4% with atenolol; p0.0001). LVH is considered to be one of the most important risk factors for cardiovascular morbidity and mortality in patients with hypertension.1 The superior regression in LVH seen with losartan was greater than that seen with atenolol and was independent of the effect of treatment on blood pressure, since blood pressure reductions in both the losartan and the atenolol treatment arms were comparable.1 An analysis of ECG indices of LVH as time-varying covariates showed only a partial (less than one third) relation with the effect of losartan based treatment on the primary outcome.1 The superior risk reduction of the primary endpoint with losartan vs. atenolol in LIIFE suggests an important role for losartan in patients with hypertension beyond the effects of LVH reduction alone.1 * * * 海捷亚治疗相关不良反应发生率与氯沙坦(科素亚)和安慰剂相似，均大大低于其它降压药物，如钙